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Acromegaly is a rare disease commonly caused by a pituitary adenoma, which overproduces growth hormone (GH) in a pulsatile manner, resulting in increased secretion of insulin-like growth factor 1 (IGF-1) \[[@CR1]--[@CR3]\]. It has an estimated prevalence of 40--70 per million in the general population \[[@CR4], [@CR5]\]. This, however, may be an underestimation with some reports of more than 100 cases per million \[[@CR6]\]. Despite being a rare disease, the burden of acromegaly is largely due to its associated comorbidities and the life-long management required \[[@CR4]\]. Untreated acromegaly is associated with increased morbidity and mortality \[[@CR7]\], and the occurrence and severity of linked complications is related to the length of exposure to excess GH \[[@CR8]\]. Furthermore, the duration of symptoms is directly associated with mortality due to the disease \[[@CR9]\], which is significantly higher than the general population \[[@CR10]\]. Unfortunately, there can be a very long delay between the appearance of initial symptoms and the diagnosis of acromegaly \[[@CR9]\], and thus its prevalence may be underestimated. Delayed diagnosis is associated with poor quality of life and worse outcomes due to the more severe complications and harder-to-treat advanced disease at the time of diagnosis \[[@CR11], [@CR12]\]. As such, early diagnosis and treatment is of the utmost importance. An earlier diagnosis would allow for earlier initiation of appropriate treatment, which in turn would lead to more successful disease management and ultimately better outcomes. As there are clear unmet needs around the recognition and diagnosis of acromegaly, there are obvious opportunities for earlier and increased detection. However, since acromegaly is uncommon, it may be challenging to set strategies that will aid in the diagnosis and early detection in a realistic and cost-effective manner.

The rationale for screening for acromegaly {#Sec2}
==========================================

Diagnosis of acromegaly is based primarily on clinical manifestations and usually confirmed by measuring GH levels, although this can be tricky due to the pulsatile nature of GH production. IGF-1, on the other hand, is more stable throughout the day and has a good correlation to GH level \[[@CR13]\]. The clinical manifestations depend on the levels of GH (and IGF-1), age, tumour size, and the delay in diagnosis. Since many of the symptoms of acromegaly are non-specific and similar to other more common diseases, diagnosis is often missed or delayed by 5--10 years from the onset of symptoms \[[@CR7]\]. This delay is also partly due to the fact that the clinical effects of excess GH occur insidiously over time. This provides a major opportunity for earlier detection, although some centres have begun showing an earlier diagnosis due to incidental findings \[[@CR31]\]. Treatment for acromegaly is effective, and biochemical control can restore life expectancy to normal, improve symptoms, and improve/reverse comorbidities, and can therefore drastically improve the quality of life of patients \[[@CR14]\]. However, if the complications are long-standing, biochemical control does not always result in reversal \[[@CR8]\]. Since the severity of complications increases with longer duration of untreated disease, and long-term complications may be harder to address through biochemical control, getting an early diagnosis and treatment is key to improving patient quality of life and long-term outcomes.

Patients typically visit a number of healthcare providers prior to diagnosis. The first manifestations and reasons for a medical visit, in most cases, are physiognomic alterations and growth of the acral parts \[[@CR11], [@CR15]\]. These are not common in patients without acromegaly, and can be evaluated using simple observations, such as a change in shoe and/or ring size \[[@CR16]\]. Surprisingly, the features present at clinical diagnosis have not changed between 1981 and 2006, and so it is clear that acromegaly remains under diagnosed and under recognized \[[@CR11]\]. Therefore, familiarization of physicians and nurses (and the general public) with these phenotypes may be one step towards increasing early detection and diagnosis. Increasing awareness of these typical early features may help to identify patients at risk, rather than addressing comorbidities, which usually appear later, are not always present, and are rarely seen in the absence of these phenotypes. Establishing screening programs for these at risk patients could make headway in diagnosing these patients earlier. It is important to note that patients present with many different types of comorbidities, including cardiovascular disease, diabetes, hypertension, sleep apnea, carpal tunnel syndrome, and goitre \[[@CR17]\], meaning increased awareness across broad spectrum of specialties is required.

General principles for a successful screening program in acromegaly {#Sec3}
===================================================================

In general, screening programs are used in a population to identify an unrecognized disease in individuals without signs or symptoms, and are designed to identify this disease earlier. When implementing a screening program, a number of key criteria need to be met for it to be worthwhile and effective. These key criteria are as follows: (1) the condition should be an important health problem; (2) there should be a treatment available for the condition; (3) facilities that allow diagnosis and treatment should be available; (4) there should be a "latent" stage of the disease; (5) there should be a test or examination currently available for the condition; (6) the test should be acceptable to the population; (7) the natural history of the disease should be adequately understood; (8) there should be an agreed policy on whom to treat; (9) the total cost of finding a case should be economically balanced in relation to medical expenditure as a whole; (10) screening should be a continuous process, and not a 'once for all' project \[[@CR18]\].

There are two main types of screening for disease: mass screening and targeted screening \[[@CR19]\]. The difference is that mass screening is offered to all, irrespective of risk, and targeted screening is offered only to those known to be at increased risk. Many screening programs exist in other disease areas with varying levels of success e.g., breast cancer \[[@CR20], [@CR21]\], colorectal cancer \[[@CR22], [@CR23]\], prostate cancer \[[@CR24], [@CR25]\], and cervical cancer \[[@CR26]\]. In the context of a rare disease such as acromegaly, mass screening would be costly and unfeasible, whereas targeted screening may be more acceptable, especially when considering the cumulative costs of treating the increasing comorbidities associated with diagnosis delay. In order to implement this kind of program, (1) there needs to be a clear definition of which groups are at high risk, and (2) an increased awareness of this association among medical professionals (and the general public).

There are limitations of screening that would need to be considered for any program to be successful. These include the possibility of false positive or negative results, and potentially overdiagnosis \[[@CR18]\]. There is also the risk of lead time and length time bias; lead time bias occurs when a test diagnoses the disease earlier, but there is no effect on the outcome of the disease, length time bias is when, for example, screening tends to detect slow-growing tumours that would not have caused death at all, or before other causes \[[@CR18], [@CR27]\]. The best way to overcome these limitations is to use a randomized controlled trial, which can be expensive and take time, but would provide the best information for evidence-based medicine. The aim of an acromegaly screening program would be to maximize the number of cases detected, while minimizing the number of people referred unnecessarily for further tests. Any screening program proposed would need to be introduced in a way that allows its quality to be measured and continuously improved. A possible starting point would be a pilot study in a chosen country before extending the program to other Latin American countries.

Some of the potential obstacles to implementing a new screening program in acromegaly are that physicians may require training and convincing to adopt new screening behaviors in their busy practice; many are not aware of the insidious nature of acromegaly or believe it is a serious, and irreversible disorder. Overcoming preconceptions about acromegaly could be a challenge, especially since many medical schools do not put a lot of focus on uncommon diseases. In addition support from health authorities and professional associations who currently do not push for screening would have to be gained. Funding, as with any screening program, would also be an important factor. Experience has shown that no screening test is perfect, and in order to implement a successful screening program in acromegaly, a number of key components should be considered. Exactly how these could be implemented is discussed below.

Blueprint for a screening program for acromegaly in Latin America {#Sec4}
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The successful implementation of a screening program for acromegaly in Latin America involves a number of key components (Fig. [1](#Fig1){ref-type="fig"}). First, there should be a plan to increase awareness of the early signs suggestive of acromegaly; this is important for doctors involved in primary care and other relevant specialties (cardiologists, diabetologists, dermatologists, rheumatologists, pulmonologists, gynecologists, odontologists, pediatricians). Second, doctors or physicians should be educated to look for acral changes in patients with sleep apnea, diabetes, insulin resistance, carpal tunnel syndrome, cardiac hypertrophy, and other common comorbidities. This education could occur via traditional courses, teleconferences, printed materials, and digital media. There should also be increased awareness of the early features of acromegaly among the general population. This would help patients ask the right questions, which in turn would help their physicians in an earlier diagnosis. The campaign should focus on simple key features such as increasing shoe and ring size, and this could occur via TV and/or radio interviews, articles in newspapers/magazines and web-based media. There may be an important role here for communications specialists, such as the *Sociedad Argentina de Periodismo Médico* (Argentina Society of Medical Journalism).Fig. 1Key steps in the development of an acromegaly screening program in Latin America

The first practical steps in implementing the screening part of the program should include: the design of a simple detection program based on offering free IGF-1 measurements for patients with warning signs, and undertaking a pilot study (either single- or multi-center) of limited duration in a given country before extending the program to other Latin American countries with the support of pharmaceutical companies. There are a number of tools available that could help physicians with the screening process, for example a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units \[[@CR28]\]. Recently more novel approaches for early identification have been proposed; a study comparing diagnostic accuracy between physicians and a computer model showed that accuracy in the computer model was 86 %, whereas that of the physicians was only 26 % \[[@CR29]\]. Similar results were seen in a recent study by Schneider et al. \[[@CR30]\] where computer analysis again was more accurate than physicians. This type of model could aid in the early diagnosis in the proposed screening program.

Conclusions {#Sec5}
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Acromegaly is a rare disease with a large burden resulting from a lack of awareness, delayed diagnosis, and increasing comorbidities with time. A screening program for acromegaly would provide opportunities for earlier diagnosis and treatment. The most efficient strategy for detecting and diagnosing acromegaly would take the form of a targeted screening program (rather than mass screening). The two key components of this screening program would be (1) increasing awareness (among the public and doctors) of groups at risk, and (2) implementing a process of referral for further testing in those patients deemed to be at high risk. This type of targeted screening program appears to be feasible in Latin America and elsewhere. The program would first need to be evaluated for logistics and cost-effectiveness in a pilot study within a selected country, before extension to other Latin American countries. The earlier diagnosis and treatment that could be provided by the success of this type of screening program, could lead to improved outcomes and hopefully cost savings in the long-term due to fewer and less severe complications that tend to manifest over time in delayed diagnosis.
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